title: Health-related quality of life in children with newly diagnosed immune thrombocytopenia.
abstract: Despite its generally transient and benign course, childhood immune thrombocytopenia has a large impact on health-related quality of life. Recently published guidelines state that quality of life should be taken into account while making decisions on management in childhood immune thrombocytopenia. We, therefore, assessed health-related quality of life in children with newly diagnosed immune thrombocytopenia in a prospective multicenter study. One hundred and seven children aged 6 months-16 years (mean age 5.57 years) were included. We used Pediatric Quality of Life Inventory™ and Kids' ITP Tools questionnaires at diagnosis and during standardized follow-up. Scores on the Pediatric Quality of Life Inventory™ Core Scales were compared with those of healthy children. Relationships between health-related quality of life scores and treatment modality, bleeding tendency and course of the disease were examined. Kids' ITP Tools proxy reports and parent self-reports showed significant higher health-related quality of life scores in children who recovered than in children with persistent immune thrombocytopenia (at 3 months: Kids' ITP Tools parent self-report score 80.85 for recovered patients (n=69) versus 58.98 for patients with persistent disease (n=21), P<0.001). No significant differences in health-related quality of life were found between children with mild or moderate bleeding or between children who received intravenous immunoglobulin or children who were carefully observed. In conclusion, health-related quality of life of children with newly diagnosed immune thrombocytopenia is not influenced by treatment modality or bleeding severity, but only by clinical course of the disease. (Dutch Trial Register identifier: NTR TC1563).
authors.affiliation: Department of Pediatric Hematology and Oncology, University Medical Center/Wilhelmina's Children Hospital, Utrecht, the Netherlands k.m.j.heitink-polle@umcutrecht.nl.
authors.forename: Katja M J
authors.initials: KM
authors.lastname: Heitink-Pollé
authors.affiliation: Psychosocial Department, Emma Children's Hospital, Academic Medical Center, Amsterdam, the Netherlands.
authors.forename: Lotte
authors.initials: L
authors.lastname: Haverman
authors.affiliation: Department of Pediatric Hematology and Oncology, University Medical Center/Wilhelmina's Children Hospital, Utrecht, the Netherlands.
authors.forename: Kim V
authors.initials: KV
authors.lastname: Annink
authors.affiliation: Department of Pediatric Hematology and Oncology, University Medical Center/Wilhelmina's Children Hospital, Utrecht, the Netherlands.
authors.forename: Sarah J
authors.initials: SJ
authors.lastname: Schep
authors.affiliation: Sanquin Blood Supply, Diagnostic Services, Amsterdam, the Netherlands.
authors.forename: Masja
authors.initials: M
authors.lastname: de Haas
authors.affiliation: Department of Pediatric Hematology and Oncology, University Medical Center/Wilhelmina's Children Hospital, Utrecht, the Netherlands.
authors.forename: Marrie C A
authors.initials: MC
authors.lastname: Bruin
mesh_terms: D000293:Adolescent; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007223:Infant; D008297:Male; D010290:Parents / Q000523:psychology; D011446:Prospective Studies; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology / Q000523:psychology*; D011788:Quality of Life; D057566:Self Report; D011795:Surveys and Questionnaires
chemical_list: D016756:Immunoglobulins, Intravenous